The introduction of new legislation in Queensland (revoking the Public Health (Medicinal Cannabis) Act 2016 (Qld)) to simplify the process for patients and doctors to access medicinal cannabis. However, there is currently lack of information on dose response and adverse events from the use of medicinal cannabis products. There have recently been a series of developments advancing the Australian medicinal cannabis industry. The outcomes of these studies will greatly assist health professionals in the prescription of medicinal cannabis products. Key developments include: Permitting the export of Australian manufactured medicinal cannabis products, subject to local demand.
There have recently been a series of developments advancing the Australian medicinal cannabis industry.
Key developments include recommendations put forward by Professor John McMillan AO aimed at reducing the regulatory burden on the medicinal cannabis industry, the Australian Capital Territory legalising possession of up to 50 grams of cannabis for an individual over 18 years of age and permitting the cultivation of up to four cannabis plants (excluding artificial cultivation), and the Australian Government announcing it will be investing AU$3 million into the industry for research.
Background
The Australian Federal Government has a...
Read the full article @ Cannabis Law Report